Zyus.V
ZYUS.V is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic solutions.
Business. ZYUS.V is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic solutions.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ZYUS.V is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic solutions.
ZYUS.V operates with a negative equity position of CAD -5,344,000 and a debt-to-equity ratio of -2.28, indicating a highly leveraged capital structure. The company's liquidity is constrained, as evidenced by a current ratio of 0.19, suggesting limited short-term liquidity to cover immediate obligations. The valuation snapshot reveals a market cap of CAD 38,613,772.89 and an enterprise value to revenue ratio of 105.56, which is significantly higher than typical for the industry, reflecting a high valuation relative to its current revenue base.
ZYUS.V's profitability is challenged, with a net loss of CAD -33,805,000 and an operating loss of CAD -34,992,000, indicating a substantial decline in profitability. The return on equity of 6.3258% is positive but modest, while the return on assets is negative at -2.3039%, suggesting inefficient use of assets to generate profit. These metrics fall below the industry norms, highlighting the company's struggle to maintain profitability in a competitive market.
The company's revenue is concentrated in a single segment, with no disclosed geographic diversification, which increases its exposure to market-specific risks. This lack of diversification could lead to volatility in revenue and earnings, particularly if the primary market experiences downturns or regulatory changes.
ZYUS.V's growth trajectory is uncertain, with a net loss in the latest reporting period and no indication of a turnaround in the near term. The company's operating cash flow is negative at CAD -9,876,000, and free cash flow is also negative at CAD -30,890,000, indicating a lack of cash generation to support operations or growth initiatives. These financial constraints may limit the company's ability to invest in research and development or expand its market presence.
The risk assessment for ZYUS.V indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential difficulties in meeting short-term obligations. The dilution risk is low, but the company's negative equity and high debt levels could lead to further dilution if additional financing is required.
Recent events, including the latest financial results and analyst estimates, indicate a lack of confidence in the company's future performance. The mean recommendation from analysts is 2.00, which is a "Hold" rating, with no strong buy or sell recommendations. The last actual EPS was -0.47 CAD, significantly below the mean estimate of -0.22 CAD, indicating a negative earnings surprise.
- ZYUS.V is a biotechnology company with a negative equity position and high leverage, indicating a challenging capital structure.
- The company's profitability is severely impacted by a large net loss and negative operating income, which are below industry norms.
- Revenue concentration in a single segment and lack of geographic diversification increase exposure to market-specific risks.
- The company's growth trajectory is uncertain, with negative operating and free cash flows limiting its ability to invest in growth initiatives.
- Analysts have a neutral outlook on the company, with a "Hold" rating and a negative earnings surprise in the latest reporting period.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,22 |
| Revenue | —no estimate | —no estimate | 448,000 CAD |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- ZYUS.V Market data — financials · 2026-05-30
- ZYUS Life Sciences Corp Market data — analyst estimates · 2026-05-30
Ownership & reference
Leadership
- Brent ZettlPresident, Chief Executive Officer
- Charlotte Moore HepburnChairman of the Board, Chief Executive Officer